^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Ovarian Cancer
    Drug:IDE161 (PARG inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

    Excerpt:
    ...Have documented evidence of genetic alterations conferring homologous recombination deficiency 4....
    Trial ID:
    NCT05787587
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    6093 / 1 - IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets homologous-recombination-deficient and PARP inhibitor resistant breast and ovarian tumors

    Published date:
    03/15/2023
    Excerpt:
    Biochemical and cellular assays demonstrate that IDE161 is a potent inhibitor of PAR chain hydrolysis and has anti-proliferative activity in breast and ovarian HRD cancer cell lines with both inherent and acquired PARPi resistance.